Caren van Roekel

278 Chapter 10 three months, there were no significant differences. Between baseline and three months post-treatment, patients in the combination group experienced more symptoms of fatigue and appetite loss, but fewer symptoms of sore mouth/tongue and diarrhea. Therefore, the worse quality of life scores were not deemed clinically relevant (106). In conclusion, radioembolization for the treatment of colorectal liver metastases is safe, with limited side effects, usually of short duration, and it is effective, with improved overall survival rates shown in multiple studies. However, its true potential can only be shown in properly selected patients, using a personalized treatment approach. In the future, robust selection criteria and personalized activity planning should be implemented.